RVNC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 107906 min ago

@ $5.59

Išleistas: 14 vas. 2024 @ 20:54

Grąža: -33.92%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 3.36 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 20:20):

Stats
Šios dienos apimtis	2.09M
Vidutinė apimtis	1.84M
Rinkos kapitalizacija	385.08M
EPS	$0 ( 2024-02-28 )
Kita pelno data	( $-0.660 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.960
ATR14	$0.00900 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Jordan Erica	Sell	2 392	Common Stock
2024-03-15	Sjuts Dustin S	Sell	2 967	Common Stock
2024-03-18	Sjuts Dustin S	Sell	9 211	Common Stock
2024-03-15	Moxie Dwight	Sell	3 269	Common Stock
2024-03-18	Moxie Dwight	Sell	8 125	Common Stock

INSIDER POWER
64.41
Last 97 transactions
Buy: 2 720 068 \| Sell: 629 333

Tūris Koreliacija

Ilgas: 0.07 (neutral)

Trumpas: -0.58 (weak negative)

Signal:(38.088) Neutral

Revance Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SYKE	0.944
SPRB	0.923
BRACU	0.922
XLRN	0.921
PIRS	0.918
ATCX	0.918
MESA	0.915
VRME	0.915
JFIN	0.913
OVID	0.907

10 Labiausiai neigiamai susiję koreliacijos
AHPI	-0.934
TUEM	-0.902
VERA	-0.881
ARDS	-0.865
CYTO	-0.86
NAKD	-0.852
LCAP	-0.85
CFV	-0.844
JRJC	-0.843
APM	-0.837

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Revance Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.20
( neutral )

-0.25
( neutral )

0.00
( neutral )

0.33
( neutral )

0.20
( neutral )

Revance Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$234.04M
Bruto pelnas:	$145.98M (62.38 %)
EPS:	$-3.83

FY	2023
Pajamos:	$234.04M
Bruto pelnas:	$145.98M (62.38 %)
EPS:	$-3.83

FY	2022
Pajamos:	$132.57M
Bruto pelnas:	$80.90M (61.03 %)
EPS:	$-4.90

FY	2021
Pajamos:	$77.80M
Bruto pelnas:	$54.39M (69.91 %)
EPS:	$-4.17

Financial Reports:

No articles found.

Revance Therapeutics Inc

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.